StockData
Regen BioPharma Inc logo

Regen BioPharma Inc (RGBP) stock

RGBPOTCPharmaceutical PreparationsFiscal year ends September 30Also trades as RGBPP
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 17, 2026Score 2/30
$0.00+0.00 (+50.00%)

Close on Oct 19, 2026Market cap $92.33KP/E –Yield –

Regen BioPharma Inc grew revenue 0.0% to $236.56K over the twelve months to Jun 30, 2026. At the latest close the market valued the company at $92.33K.

Revenue
$236.56K
0.0% vs. a year earlier
Operating income
-$803.86K
TTM Q3 2026
EPS, diluted
-$0.05
FY2025

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026

Valuation

Market cap
$92.33K
P/E ratio
–
Price to sales
0.39
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Revenue
$236.56K
Net income
-$1.19M
EPS, diluted
-$0.05
Book value per share
-$0.01
Diluted shares
616M

Trading

Previous close
$0.00
Open
$0.00
Day's range
$0.00 – $0.00
Volume
537,125
Average volume (20 days)
3,815,881

Market cap history

Month-end market cap since 2014, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodRGBPS&P 500DifferenceRGBP per yearS&P 500 per year
1 month+50.0%+0.6%+49.4 pts
3 months+50.0%+3.4%+46.6 pts
Year to date-98.0%+13.3%−111.3 pts
1 year-98.8%+16.6%−115.5 pts
3 years-100.0%+86.4%−186.4 pts-94.4%+23.1%
5 years-100.0%+81.9%−181.9 pts-90.1%+12.7%
10 years-100.0%+318.9%−418.9 pts-73.5%+15.4%

Fourteen years at a glance

Fiscal years 2012 to 2025 and trailing twelve months, USD

Revenue

$236.56K0.0% YoY

Operating income

-$803.86K

Net income

-$1.19M

EPS, diluted

–
Reported periodTrailing twelve months

Press releases

Releases Regen BioPharma filed with the SEC as exhibits to Form 8-K or 6-K

About Regen BioPharma

Pharmaceutical Preparations

Regen Biopharma, Inc. is a biotechnology company focused on developing regenerative medicine therapies. The company targets treatments across oncology and aplastic anemia, with therapeutic candidates including HemaXellerate, dCellVax, tCellVax, DiffronC, and DuraCar, alongside patented small molecules targeting NR2F6. Its programs incorporate cellular compositions, siRNA gene silencing, mRNA cancer vaccines, and CAR-T cell engineering. Regen Biopharma advances its pipeline through internal development and commercialization partnerships, including licensing arrangements that grant external entities rights to apply its technologies toward veterinary therapeutics and human pancreatic cancer treatments.

Company profile, executives and history

Regen BioPharma stock: common questions

What is Regen BioPharma's stock price?

RGBP closed at $0.00 on Oct 19, 2026, up 50.00% on the day.

What is Regen BioPharma's market cap?

Regen BioPharma was worth $92.33K at the close on Oct 19, 2026: the share price times the diluted shares outstanding.

What is RGBP's P/E ratio?

Regen BioPharma lost money over fiscal 2025 (diluted EPS -$0.05), so it has no meaningful P/E ratio.

How much revenue does Regen BioPharma make?

Regen BioPharma reported revenue of $236.56K for the twelve months to Jun 30, 2026, up 0.0% from a year earlier.

Does Regen BioPharma pay a dividend?

No. Regen BioPharma has not paid a cash dividend over the last twelve months.

How has RGBP stock performed over the past year?

Including dividends, RGBP returned -98.8% over the past year, against +16.6% for the S&P 500.

Who are Regen BioPharma's competitors?

Companies most similar to Regen BioPharma by business, industry and size include LIPO, ERNA, GDTC, RDHL, ABVC.

See a number that looks wrong?